The authors concluded that combining the VEGF inhibitor (i.e, sorafenib) and the selective MET inhibitor (i.e, tivantinib) might provide synergistic or additive anti-tumor activity overcoming the resistance to sorafenib in treating advanced solid tumors, including HCC. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.